Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This study was planned to compare deferasirox and desferrioxamine in terms of mean serum ferritin levels in patients of β-thalassemia major having Iron overload. Choosing an effective iron chelator is crucial to increasing iron chelation therapy compliance. Not much local data exists in Pakistan comparing the effectiveness of deferasirox (DFX) and desferrioxamine (DFO), so, this study would be helpful in providing baseline data and formulating new protocols for iron chelation therapy, in which DFX may be a useful oral alternative to parenteral DFO.
Epistemonikos ID: 13b39d29156ae3a6e5f1241cbef0f8079a7342f2
First added on: Jul 01, 2024